Daniel Delorme

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i>

Marielle Fournel, Claire Bonfils, Yu Hou et al. · Molecular Cancer Therapeutics · 2008 · 333 citations · Full text

Tumor Biology, Inhibitory Activity, Medicine +13

Design and reactivity of topologically unique, chiral phosphonamides. Remarkable diastereofacial selectivity in asymmetric olefination and alkylation

Stephen Hanessian, Daniel Delorme, Serge Beaudoin et al. · Journal of the American Chemical Society · 1984 · 163 citations

Derivative (Chemistry), Engineering, Alkene Metathesis +14

New Diarylmethylpiperazines as Potent and Selective Nonpeptidic δ Opioid Receptor Agonists with Increased In Vitro Metabolic Stability

Niklas Plobeck, Daniel Delorme, Zhongyong Wei et al. · Journal of Medicinal Chemistry · 2000 · 115 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +15

Mild cleavage of methoxymethyl (MOM) ethers with trimethylsilyl bromide

Stephen Hanessian, Daniel Delorme, Yves Dufresne · Tetrahedron Letters · 1984 · 114 citations

Organic Chemistry, Organometallic Catalysis, Chemistry +1

Discovery of <i>N</i>-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

Nancy Zhou, Oscar Moradei, Stéphane Raeppel et al. · Journal of Medicinal Chemistry · 2008 · 108 citations · Full text

Compound 8, Chemoprevention Strategy, Pharmacotherapy +18